In vitro effects of the active metabolite of leflunomide, A77 1726, on feline herpesvirus-1

American Journal of Veterinary Research

Volumn 68, Issue 9, 2007, Pages 1010-1015

  Williams, Courtney R ^a,c   Sykes, Jane E ^a   Mehl, Margo ^a   MacLeod, Jennifer S ^a   Lindsay, LeAnn L ^a   Poland, Amy M ^a,d   Chen, Yi Je ^a   Kyles, Andrew E ^a,e   Waldman, W James ^b   Gregory, Clare R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Flatiron Veterinary Specialists   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e Florida Veterinary Specialists   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; DRUG METABOLITE; LEFLUNOMIDE; LIPOCORTIN 5; PROPIDIUM IODIDE; TERIFLUNOMIDE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CAT; CELL COUNT; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DRUG EFFECT; FELINE HERPES VIRUS 1; HERPES VIRUS; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY CELL CULTURE; MITOCHONDRION; MONOLAYER CULTURE; NONHUMAN; ORGAN TRANSPLANTATION; REAL TIME POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; VIRUS INHIBITION; VIRUS LOAD; VIRUS MORPHOLOGY; VIRUS PARTICLE; VIRUS PLAQUE; VIRUS REPLICATION;

ANILINE COMPOUNDS; ANIMALS; ANTIVIRAL AGENTS; APOPTOSIS; CAT DISEASES; CATS; CELL LINE; CELL SURVIVAL; DNA, VIRAL; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HYDROXYBUTYRATES; ISOXAZOLES; MICROSCOPY, ELECTRON, TRANSMISSION; MITOCHONDRIA; POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; VIRAL LOAD; VIRUS REPLICATION;

FELID HERPESVIRUS 1; FELIDAE;

EID: 34548634388     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.68.9.1010     Document Type: Article

References (37)

1. Kadar E, Sykes JE, Kass PH, et al. Evaluation of the prevalence of infections in cats after renal transplantation: 169 cases (1987-2003). J Am Vet Med Assoc 2005;227:948-953.
2. Stiles J. Feline herpesvirus. Clin Tech Small Anim Pract 2003;18:178-185.
3. Elder RT, Xu X, Williams JW, et al. The immunosuppressive metabolite of leflunomide, A77 1726, affects routine T cells through two biochemical mechanisms. J Immunol 1997;159:22-28.
4. Gregory CR, Bernsteen L. Organ transplantation in clinical veterinary practice. In: Slatter D, ed. Textbook of small animal surgery. Philadelphia: WB Saunders Co, 2003;122-136.
5. Bartlett RR, Dimitrijevic M, Mattar T, et al. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 1991;32:10-21.
6. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: effects on NK-κB, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 2000;165:5962-5969.
7. Li EK, Tam LS, Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis. Clin Ther 2004;26:447-459.
8. Van Roon EN, Jansen TL, Houtman NM, et al. Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Safety 2004;27:345-352.
9. Gregory CR, Stewart A, Sturges B, et al. Leflunomide effectively treats naturally occurring immune-mediated and inflammatory diseases of dogs that are unresponsive to conventional therapy. Transplant Proc 1998;30:4143-4148.
10. McChesney L, Xiao F, Sankary H, et al. An evaluation of leflunomide in the canine renal transplantation model. Transplantation 1994;57:1717-1722.
11. Williams JW, Xiao F, Presto FF, et al. Leflunomide in experimental transplantation - control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine. Transplantation 1994;57:1223-1231.
12. Silva HT, Morris RE. Leflunomide and malononitrilamides. Exp Opin Invest Drug 1997;6:51-64.
13. Williams JW, Mital D, Chong A, et al. Experiences with leflunomide in solid organ transplantation. Transplantation 2002;73:358-366.
14. Chong AS, Zeng H, Knight DA, et al. Concurrent antiviral and immunosuppressive activities of leflunomide, in vivo. Am J Transplant 2006;6:69-75.
15. Knight DA, Hejmanowski AQ, Dierksheide JE, et al. Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide. Transplantation 2001;71:170-174.
16. Waldman WJ, Knight DA, Blinder L, et al. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology 1999;42:412-418.
17. John GT, Manivannan J, Chandy S, et al. A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients. Transplant Proc 2005;37:4303-4305.
18. Waldman WJ, Knight DA, Lurain NS, et al. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation 1999;68:814-825.
19. John GT, Manivannan J, Chandy S, et al. Leflunomide therapy for cytomegalovirus disease in renal allograft recipients. Transplantation 2004;77:1460-1461.
20. Avery RK, Bolwell BJ, Yen-Lieberman B, et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant 2004;34:1071-1075.
21. Nassise MP, Guy JS, Davidson MG, et al. Experimental ocular herpesvirus infection in the cat. Sites of virus replication, clinical features and effects of corticosteroid administration. Invest Ophthal Vis Sci 1989;20:1758-1768.
22. Vogtlin A, Fraefel C, Albini S, et al. Quantification of feline herpesvirus 1 DNA in ocular fluid samples of clinically diseased cats by real-time TaqMan PCR. J Clin Microbiol 2002;40:519-523.
23. Gemeniano MC, Sawai ET, Leutenegger CM, et al. Feline immunodeficiency virus ORF-A is required for virus particle formation and virus infectivity. J Virol 2003;77:8819-8830.
24. Kelley GO, Zagmutt-Vergara FJ, Leutenegger CM, et al. Evaluation of five diagnostic methods for the detection and quantification of Myxobolus cerebralis. J Vet Diagn Invest 2004;16:202-211.
25. Gilad O, Yun S, Zagmutt-Vergara FJ, et al. Concentrations of a Koi herpesvirus (KHV) in tissues of experimentally infected Cyprinus carpio koi as assessed by real-time TaqMan PCR. Dis Aquat Organ 2004;60:179-187.
26. Vermes I, Haanen C, Seffens-Nakken H, et al. A novel assay of apoptosis. Flow cytometric detection of phosphatidlyserine expression on early apoptotic cells using fluorescein labeled Annexin V. J Immunol Methods 1995;184:39-51.
27. Loo DT, Rillema JR. Measurement of cell death. In: Mather JP, Barnes D, eds. Methods in cell biology. San Diego: Academic Press Inc, 1998;251-264.
28. Guba M, Graeb C, Jauch K, et al. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004;77:1777-1782.
29. Wooldridge JD, Gregory CR, Mathews KG, et al. The prevalence of malignant neoplasia in feline renal-transplant recipients. Vet Surg 2002;31:94-97.
30. Grinyo JM, Cruzado JM. Steroid or calcineurin inhibitor-sparing immunosuppressive protocols. Contrib Nephrol 2005;146:30-42.
31. Fung J, Kelly D, Kadry Z, et al. Immunosuppression in liver transplantation: beyond calcineurin inhibitors. Liver Transpl 2005;11:267-280.
32. Singh N. Infectious complications in organ transplant recipients with the use of calcineurin-inhibitor agent-based immunosuppressive regimens. Curr Opin Infect Dis 2005;18:342-345.
33. Gregory CR, Morris RE. Strategies in the prevention of chronic rejection. Curr Opin Organ Transpl 1998;3:19-22.
34. Xu X, Williams JW, Bremer EG, et al. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 1995;270:12938-12403.
35. Mattar T, Kochhar K, Bartlett R, et al. inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. Fed Eur Biochem Soc 1993;334:161-164.
36. Salvi M, Brunati AM, Toninello A. Tyrosine phosphorylation in mitochondria: a new frontier in mitochondrial signaling. Free Radic Biol Med 2005;38:1267-1277.
37. Augereau O, Claverol S, Boudes N, et al. Identification of tyrosine-phosphorylated proteins of the mitochondrial oxidative phosphorylation machinery. Cell Mol Life Sci 2005;62:1478-1488.